Ionis Pharmaceuticals, Inc. Share Price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:04 17/05/2024 am IST 5-day change 1st Jan Change
37.62 USD -4.06% Intraday chart for Ionis Pharmaceuticals, Inc. -6.32% -25.64%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 599M 49.97B Sales 2025 * 767M 63.99B Capitalization 5.72B 477B
Net income 2024 * -575M -47.99B Net income 2025 * -518M -43.23B EV / Sales 2024 * 8.6 x
Net cash position 2024 * 567M 47.32B Net Debt 2025 * 318M 26.54B EV / Sales 2025 * 7.87 x
P/E ratio 2024 *
-9.89 x
P/E ratio 2025 *
-11.3 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.06%
1 week-6.32%
Current month-8.82%
1 month-9.46%
3 months-16.92%
6 months-24.41%
Current year-25.64%
More quotes
1 week
36.75
Extreme 36.75
39.78
1 month
36.75
Extreme 36.75
43.76
Current year
36.75
Extreme 36.75
54.44
1 year
35.44
Extreme 35.4401
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
73.09
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 01/12/01
Founder 62 10/89/10
Director of Finance/CFO 62 01/00/01
Members of the board TitleAgeSince
Chairman 72 03/14/03
Founder 62 10/89/10
Director/Board Member 70 10/19/10
More insiders
Date Price Change Volume
16/24/16 37.62 -4.06% 3,272,357
15/24/15 39.21 +2.46% 1,256,373
14/24/14 38.27 -1.37% 983,112
13/24/13 38.8 -0.72% 1,045,266
10/24/10 39.08 -0.99% 895,065

Delayed Quote Nasdaq, May 17, 2024 at 01:30 am IST

More quotes
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
39.21 USD
Average target price
57.95 USD
Spread / Average Target
+47.79%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW